Atomo Diagnostics is a multi-award winning and rapidly growing medical device company that has developed and commercialised AtomoRapid™, the world’s first integrated device for blood based immunoassay rapid diagnostic testing (RDTs) in point of care settings.
Atomo launched its first test on the platform, AtomoRapid HIV, in 2014. Since launch, AtomoRapid tests have quickly established themselves as a “best in class” solution for professional use diagnostic screening.
With tests now commercialised for HIV and malaria and a rapid Ebola test ready for launch later this year, Atomo is disrupting global RDT markets where convenience, usability and safety have for many years been largely overlooked.
Please listen to John Kelly, CEO of Atomo Diagnostics below.